psychiatry-2019-keynote

2 / 10

Psychiatry 2019 Journal Clinical Psychiatry and Cognitive Psychology | Volume 3
Page 13
May 20-21, 2019 | Rome, Italy
PSYCHIATRY AND
PSYCHOLOGICAL DISORDERS
2nd International Conference on OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
MEDICAL CANNABIS FOR AUTISM
SPECTRUM DISORDER, IS IT AN OPTION?
Objective: A literature reviewwas conducted to evaluate the validity of med-
ical cannabis as an adjunctive treatment in the management of individuals
with autism spectrum disorders.
Background: Autism spectrum disorder (ASD) is a developmental disability
that can cause significant social, communication and behavioral challenges.
The learning, thinking and problem-solving abilities of people with ASD can
range from gifted to severely challenged people. Since there is no medical
test to diagnose the disorders, the provider must listen to the parent/caretak-
er and look at the child’s behavior and development tomake a diagnosis. Un-
fortunately, many children do not receive a final diagnosis until much older.
A deficiency in the endocannabinoid system in the body is considered as the
reason for many disorders and recent researcher’s state that it might help in
the treatment of autism. The chronic neuro inflammation can be eased with
the help of the antioxidants which are present in the cannabis plant. The the-
ory of CED was based on the concept that many brain disorders are associat-
ed with neurotransmitter deficiencies, affecting acetylcholine in Alzheimer’s
disease, dopamine in Parkinsonian syndromes, serotonin and norepineph-
rine in depression and that a comparable deficiency in endocannabinoid lev-
els might be manifest similarly in certain disorders that display predictable
clinical features as sequelae of this deficiency.
Design & Methods: A literature review was conducted at the National Cen-
ter for Biotechnology Information, US National Library of Medicine PubMed
from 2012-2018 specific to the topic of medical cannabis and autism spec-
trum disorder.
Conclusion: This literature review supports the feasibility of cannabis based
medicine as a promising treatment option in children with ASD. Based on the
promising results, it is recommended that large, double blind, placebo con-
trolled cross-over trials was launched in jurisdictions wheremedical cannabis
can be studied without limitations from the federal government.
Joseph Rosado, J Clin Psychiatry Cog Psychol 2019, Volume 3
Joseph Rosado, after spending several years in
central Florida working as an orderly, then an
EMT/Paramedic and Heart cath lab technician, he
realized his passion for the medical profession.
He started chiropractic school at Life College in
Marietta, GA where he graduated cum laude with
a BS degree in Clinical Nutrition and a Doctor of
Chiropractic Degree. After practicing for sever-
al years, he went on to Universidad Central del
Este; in San Pedro de Macoris in 2001 he gradu-
ated summa cum laude with his medical degree.
He completed his MBA in Health Care Manage-
ment from University of Phoenix and graduated
magna cum laude in 2005. He has worked as a
Physician, Clinic and Hospital Director, Director
of the Communicable Disease Division/Epidemi-
ology and Immunization Departments. Currently
he is the Medical Director of a Medical Cannabis
Clinic, President/CEO of International Medical
Consultants and volunteers once a month at a
community clinic. He is on the bureau of speak-
ers for political campaigns, cannabis advocacy
and medical cannabis dispensaries in the United
States, Canada, Mexico, Thailand and Colombia,
as well as published multiple articles on the use
of medical cannabis. He has worked with close to
2,000 patients, which include infants, toddlers,
children, adolescents, adults and geriatrics for
the evaluation, recommendation and manage-
ment of medical cannabis till date.
Joseph Rosado
International Medical Consultants, USA
BIOGRAPHY